At the IGTP TODAY

News

- Research

According to a study by the Inflammatory Bowel Disease Research Group, severe obesity is a risk factor for developing Crohn’s disease and ulcerative colitis

This is the main conclusion of a study that analysed data over a fifteen-year period from one million individuals in Catalonia with obesity, severe obesity, or who had undergone bariatric surgery. Crohn's disease and ulcerative colitis are the main inflammatory bowel diseases, affecting around 100,000 people in Catalonia, which today marks World IBD Day.

- Research

A new cell model to advance research into NF2-related schwannomatosis

A study led by the Clinical Genomics Unit (UGC) has established a new cell model to advance research into NF2-related schwannomatosis (SWN-NF2), a rare genetic disease. The work, published in the journal Genes & Disease, describes the generation and characterisation of cell spheroids derived from induced pluripotent stem cells (iPSC)-a type of stem cell capable of transforming into almost any cell type-that reproduce the alterations observed in tumours associated with the disease.

- Research

HDAC11 deficiency improves muscle function and regeneration during ageing

Researchers from GRENBA-IGTP have identified the HDAC11 protein, an enzyme involved in cellular regulation, as a new therapeutic target to combat sarcopenia, the loss of muscle mass associated with ageing. The study shows that HDAC11 deficiency reduces muscle atrophy, preserves the muscle stem cell reservoir, promotes regeneration after injury and improves muscle function, opening the door to new strategies to support healthy ageing.

- Research

IGTP-led study identifies an epigenetic signature with prognostic value in metastatic thyroid cancer

Researchers from the Endocrine Tumours group, in collaboration with five university hospitals, have conducted the first comprehensive study of DNA methylation patterns in metastatic differentiated thyroid cancer (DTC). Published in the journal Thyroid, the study identifies an epigenetic signature comprising 156 CpG sites in primary tumours that could help stratify patients according to their risk of developing distant metastases.